Join the club for FREE to access the whole archive and other member benefits.

Matthew O’Connor

Co-Chief Executive Officer and Co-founder of Cyclarity Therapeutics (former Underdog Pharmaceuticals)

Dr. O’Connor was awarded his Master’s degree in neuroscience from Northwestern Medical in 1999 and his PhD in Biochemistry from Baylor College of Medicine in 2005. His postdoctoral research includes work at UC Berkeley on muscle stem cells and aging. He is the author of 10 published manuscripts and lead inventor on the cyclodextrin patents. He is the outgoing VP of Research at SENS Research Foundation.

Visit website:


See also: Company Cyclarity Therapeutics - Company developing simple and direct interventions targeting toxic forms of cholesterol for age-related diseases.

Matthew O’Connor is also referenced in the following:


Research company that helps people join the Longevity Biotechnology industry through education and more

Longevity Hackers

Feature length documentary about longevity and radical life extension with due to be released in 2023

Longevity Summit Dublin 2022

18-Sep-2022 to 20-Sep-2022

Event gathering Global Longevity and Rejuvenation community in Dublin with many longevity movement superstars as speakers

SENS Annual Report 2020

Quick summary of SENS’ latest research projects and other activities

Matthew O’Connor Blog Posts

Highlights of Ending Age-Related Diseases 2020

Highlights of Ending Age-Related Diseases 2020

Key points from 20 presentations from world-leading researchers

Matthew O’Connor News

'Innovation Passport' awarded for Underdog's novel compound intended for treating heart diseases

Longevity Technology - 09-Sep-2021

Safe and potential compound shows disease-modifying effect by removing toxic cholesterol from blood